Enesi Pharma’s ImplaVax®-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine

Enesi Pharma’s ImplaVax®-Enabled, Solid-Dose Recombinant Classical Swine Fever (CSF) Vaccine Produces Immune Responses Superior to Liquid Vaccine

·         Second positive study in important animal health indications using different vaccine constructs demonstrates potential of ImplaVax®-enabled needle-free thermally stable solid-dose vaccination platform with read-through to human health

OXFORD, UK – 6 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive top-line results from a new study evaluating the immune responses generated by an ImplaVax®-enabled unit solid-dose formulation of classical swine fever (CSF) vaccine.

The results showed that a novel solid-dose ImplaVax® formulation of a recombinant E2 antigen CSF virus vaccine delivered subcutaneously using the ImplaVax® needle-free injection device generated a stronger immune response than standard liquid CSF vaccine formulations, particularly in terms of CSF virus-specific T-cell responses.

CSF is a significant animal health issue that causes a highly contagious haemorrhagic fever in pigs, which is deadly in its acute form. Due to its severe economic impact, CSF is notifiable to the world organisation for animal health (OIE). The disease is endemic in parts of Asia with significant adverse impacts on animal health, food security and the pig industry. Despite extensive efforts in CSF virus research, diagnostics and eradication, the virus continues to persist and re-emerge, posing a threat for food supply in affected regions¹.

More details of the study and its results will be presented in an upcoming publication.

David Hipkiss, Enesi Pharma CEO, commented:

“We are delighted to report positive top-line results from this successful study. These new results with a solid-dose recombinant protein subunit vaccine reinforce the strong potential of ImplaVax® in the growing global animal health market, and build on the recent positive results in Porcine Reproductive and Respiratory Syndrome (PRSS) with a solid-dose live attenuated virus vaccine undertaken with The Pirbright Institute.

“In particular, these results highlight the applicability of the ImplaVax® platform across multiple proven vaccine formats and into human health given the relative similarity of skin models and immune responses between pigs and humans. This gives us confidence in the potential of our ImplaVax®-enabled solid-dose vaccine formats to generate positive results and demonstrate the myriad associated benefits in our many other partnerships and applications targeting infectious diseases in humans.”

References

¹ Ganges et al, Classical swine fever virus: the past, present and future, Virus Research (2020) 289 ,198151,

https://doi.org/10.1016/j.virusres.2020.198151